Detalhe da pesquisa
1.
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity.
Nature
; 623(7989): 1034-1043, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37993715
2.
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.
Mol Cell
; 81(18): 3833-3847.e11, 2021 09 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34289383
3.
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
Blood
; 141(17): 2047-2061, 2023 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36724453
4.
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
Blood
; 140(11): 1200-1228, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35767897
5.
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.
Haematologica
; 2024 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38618681
6.
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
Ann Hematol
; 103(1): 105-116, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38036712
7.
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Blood
; 137(13): 1792-1803, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33024987
8.
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
Am J Hematol
; 98(2): 272-281, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36309981
9.
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
Blood
; 136(6): 674-683, 2020 08 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32285126
10.
A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Cancer
; 127(16): 2943-2953, 2021 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33934351
11.
Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat.
Haematologica
; 106(9): 2397-2404, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32732354
12.
How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms.
Blood
; 132(22): 2339-2350, 2018 11 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-30333119
13.
A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia.
Am J Hematol
; 95(8): 937-943, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32311140
14.
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.
Biol Blood Marrow Transplant
; 24(5): 997-1004, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29288821
15.
Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions.
Cancer
; 124(24): 4601-4609, 2018 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30289970
16.
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.
N Engl J Med
; 373(10): 920-8, 2015 Sep 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26332546
17.
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors.
Haematologica
; 108(8): 2234-2239, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36655425
18.
Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning.
Biol Blood Marrow Transplant
; 22(6): 1065-1072, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26912055
19.
Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.
Blood
; 123(23): 3574-7, 2014 Jun 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-24687085
20.
Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
Haematologica
; 101(5): 634-43, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26869630